Retatrutide
TRIUMPH-2
Eli Lilly · Phase 3 · Completed · Enrollment 1152
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Retatrutide Dose 1 | n/r | n/r | n/r | n/r |
| Retatrutide Dose 2 | n/r | n/r | n/r | n/r |
| Retatrutide Dose 3 | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- Retatrutide Dose 1: endpoint not reported
- Retatrutide Dose 2: endpoint not reported
- Retatrutide Dose 3: endpoint not reported
- Placebo: endpoint not reported